The newspaper said the Supreme Court ruling had "clarified that it does not mean no minorvariations are patentable - that assessment depends on the therapeutic efficacy".
Such variability could be due to environmental factors, but Dr Gibson suspected it might actually be due to minorvariations in the healthy copy of the Egfr gene.